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Where do we stand with antithrombotic prophylaxis in patients with COVID-19?
From Dec 2019 onwards, an outbreak of cases of pneumonia asso-
ciated with novel Coronavirus (SARS-CoV2) has been reported in China.
The disease, defined ‘COVID-19’, since Jan 2020 has spread in Italy,
particularly in Milan and other cities in Northern Italy. On March 11,
the WHO declared COVID-19 a pandemic. The mortality rate in Italy
exceeds 12% and is up to 26% in intensive care units (ICUs) [1]. After
an early phase characterized by mild symptoms, patients with COVID-
19 infection may develop an interstitial pneumonia associated with an
acute inflammatory state [2]. Autopsy findings showed the occlusion on
the small vessels of the lungs (and also other organs) [3], possibly be-
cause of an intense cytokines secretion associated to an endothelial
impairment bringing to the activation of the coagulation cascade.
An interim guidance on COVID-19 coagulopathy released on Mar 25
by experts of the International Society of Thrombosis and Haemostasis
(ISTH) suggests a conventional prophylactic dose of enoxaparin 4000 U
(or equivalent dose of another low molecular weight heparin) once
daily [4]. However, the same prophylactic dose is insufficient to pre-
vent venous thromboembolism in non-COVID-19 ICU patients, who
develop pulmonary embolism 10% of cases [5]. This figure was per-
ceived even higher since the beginning of epidemic in many ICUs, and
Klok and colleagues confirmed a 31% cumulative incidence of throm-
bosis in a cohort of 184 ICU patients with COVID-19, despite antith-
rombotic prophylaxis at least at the conventional doses. The vast ma-
jority of the events (81%) were pulmonary emboli [6]. It is easy to
imagine how pulmonary embolism can dramatically worsen the re-
spiratory function of COVID-19 patients and increase their mortality.
Another aspect that should be considered is the difficulty to perform
CT-scan in many hospitals due to the emergency that several countries
are facing. Not all ICU patients who deserve a chest CT scan for sus-
pected pulmonary embolism are promptly diagnosed and indirect ob-
jective examinations, i.e., echocardiography or lung ultrasonography
do not help. It may be that an unexpected worsening of the respiratory
function together with a sudden increase of D-dimer levels are sug-
gestive of pulmonary embolism, but this remains to be demonstrated.
To date, D-dimer levels help in predicting the severity of the disease and
patient's prognosis, as patients with high levels at admission die more
than those with normal levels [7].
With this panorama and all the uncertainties of care of ICU patients
with COVID-19, we believe that when pulmonary embolism is sus-
pected objective diagnosis should be performed quickly and appro-
priate heparin doses administered. If diagnosis is delayed, consider sub-
therapeutic or therapeutic heparin regimens in patients with low risk of
bleeding. On Apr 11, the Italian Medicines Agency (AIFA) published a
document on heparin use in COVID-19 patients, suggesting doses close
to therapeutic ones in severe cases, despite the lack of scientific evi-
dence. Further studies are urgently needed to establish the optimal
heparin treatment in ICU patients with COVID-19.
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